|This article needs additional citations for verification. (November 2014)|
A wakefulness-promoting agent, or eugeroic, is a type of drug which specifically improves wakefulness and alertness, and reduces tiredness, drowsiness, and the need for sleep. They are used mainly in the treatment of sleeping disorders, excessive daytime sleepiness and narcolepsy, though they are also used merely to counteract fatigue and lethargy and to enhance motivation and productivity. Wakefulness-promoting agents appear to function primarily by increasing catecholaminergic (adrenergic, dopaminergic), histaminergic, and orexinergic activity in the brain. Unlike many other stimulants, wakefulness-promoting agents are relatively non-addictive and non-dependence-forming.
The prototypical eugeroic is modafinil, and other drugs include adrafinil and armodafinil. The primary difference between these drugs and amphetamine-like stimulants is that wakefulness-promoting agents specifically trigger activation of neurons in the hypothalamus-based wakefulness circuits, as opposed to producing diffuse neuronal activation.
- Adrafinil (Olmifon)
- Armodafinil (Nuvigil)
- CRL-40,941 (a.k.a. fladrafinil or fluorafinil)
- Modafinil (Provigil, Alertec)
- Fluorenol (a.k.a. hydrafinil)
- Ballon, D.D.; Feifel, D. (2006). "A systematic review of modafinil: potential clinical uses and mechanisms of action". Journal of Clinical Psychiatry 67 (4): 554–66. doi:10.4088/JCP.v67n0406. PMID 16669720. Retrieved June 11, 2010. (subscription required (. ))
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|